I think you underestimate the potential TAUG has for upside since taking a stake in VTGN and controlling 620,000 shares.
First Phase 2 in the NIH Monotherapy, the trial you keep alluding to is a new trial Phase 2 adjunctive. DO YOU UNDERSTAND THE DIFFERENCE NOW, Capiche.
The NIH Phase 2a MONOTHERAPY study is expected by late second quarter. But that is up to the NIH.
The NIH not only funded this Phase 2a trial, the funds were switched to AV101 for depression as opposed to pain, the original Phase 2a trial was going to be for pain.
The phase 2A monotherapy could be completed as early as the end of Q2, but that controlled by the NIH. That is a roughly 8 million dollar study funded entirely by the NIH and while it is a small patient trial that will not provide robust efficacy data it will provide important markers as to how the drug interacts with the brain and safety. My thought is if the NIH saw any safety concerns the trial would be stopped.
What we do know is;
1. the Company is funded
2. the US patent is approved and is strong (over 40 mil shares traded the day the patent was announced and the stock went up 250%)
3. the FDA accepted and approved a better compound
4. the FDA gave VTGN fast track designation
5. AV-101 has other potential indications, pain, Hodgkinson's, Parkinsons
6. The depression drug space is now hot, with Alkemes, Sage, and AGN all getting in big. J&J is close to getting a ketamine nasal drug approved.
AV-101 could be better than all of them
TAUG made a great move with VTGN, and if the common is sold TAUG would still hold 360,000 warrants exercisable at 1.5 RISK FREE.
Chardan is the first brokerage to really cover and do anaysis of VTGN and they are calling for $22.00 fully diluted.
AI
